A drug that slows the progression of Alzheimer's has been approved for use for the first time in America.
Leqembi works on those with mild or the early stages of the disease and is given intravenously every two weeks.
Up to now, other medicines have targeted Alzheimer's symptoms, but this drug focuses on a protein in the brain thought to be one of its main causes.
